{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:41:46Z","timestamp":1776778906570,"version":"3.51.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"suppl_9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1093\/infdis\/jix407","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T15:10:25Z","timestamp":1502291425000},"page":"S838-S842","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries"],"prefix":"10.1093","volume":"216","author":[{"given":"George K","family":"Siberry","sequence":"first","affiliation":[{"name":"Office of the US Global AIDS Coordinator, US Department of State"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Amzel","sequence":"additional","affiliation":[{"name":"Prevention Care and Treatment Division, Office of HIV\/AIDS, Global Health Bureau, US Agency for International Development"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Ramos","sequence":"additional","affiliation":[{"name":"International Laboratory Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia D","family":"Rivadeneira","sequence":"additional","affiliation":[{"name":"Maternal and Child Health Branch, Division of Global HIV\/TB, Center for Global Health, Centers for Disease Control and Prevention"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"key\n\t\t\t\t20180306121514_CIT0001","author":"International Center for AIDS Care and Treatment Program (ICAP) Columbia University"},{"key":"key\n\t\t\t\t20180306121514_CIT0002","author":"UNAIDS"},{"key":"key\n\t\t\t\t20180306121514_CIT0003","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0000000000000261","article-title":"Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis","volume":"28","author":"Kuhn","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121514_CIT0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/jac\/dkw039","article-title":"Prevalence and dynamics of the K65R drug resistance mutation in HIV-1\u2013infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk","volume":"71","author":"Inzaule","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121514_CIT0005","doi-asserted-by":"crossref","first-page":"e1000430","DOI":"10.1371\/journal.pmed.1000430","article-title":"HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis","volume":"8","author":"Zeh","year":"2011","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180306121514_CIT0006","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/cid\/cir008","article-title":"Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants","volume":"52","author":"Fogel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121514_CIT0008","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1000931","article-title":"Antiretroviral treatment for children with peripartum nevirapine exposure","volume":"363","author":"Palumbo","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306121514_CIT0009","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children","volume":"366","author":"Violari","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306121514_CIT0010","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/cid\/ciw488","article-title":"Nevirapine- versus lopinavir\/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial","volume":"63","author":"Barlow-Mosha","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0011","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","author":"World Health Organization","edition":"2nd ed"},{"key":"key\n\t\t\t\t20180306121514_CIT0012","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2015.13631","article-title":"Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial","volume":"314","author":"Coovadia","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180306121514_CIT0013","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/cid\/cix335","article-title":"Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term outcomes of a randomized trial","volume":"65","author":"Murnane","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0014","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/INF.0000000000000222","article-title":"Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis","volume":"33","author":"Technau","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180306121514_CIT0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1473-3099(15)00319-9","article-title":"Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial","volume":"16","author":"Mulenga","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0016","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/QAD.0000000000000438","article-title":"Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland","volume":"28","author":"Duong","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121514_CIT0017","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306121514_CIT0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40272-016-0210-4","article-title":"Challenges and opportunities in the development of HIV medications in pediatric patients","volume":"19","author":"Dubrocq","year":"2017","journal-title":"Paediatr Drugs"},{"key":"key\n\t\t\t\t20180306121514_CIT0019","article-title":"Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to <6 years old [","author":"Ruel","year":"2017"},{"key":"key\n\t\t\t\t20180306121514_CIT0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-6405-10-25","article-title":"Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic","volume":"10","author":"Sebunya","year":"2013","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20180306121514_CIT0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/QAI.0000000000000671","article-title":"HIV-1 drug resistance and second-line treatment in children randomized to switch at low versus higher RNA thresholds","volume":"70","author":"Harrison","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121514_CIT0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAD.0000000000001273","article-title":"Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern","volume":"31","author":"Muri","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121514_CIT0023","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/cid\/ciw645","article-title":"Suboptimal viral suppression rates among HIV-infected children in low- and middle-income countries: a meta-analysis","volume":"63","author":"Boerma","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/aid.2012.0283","article-title":"Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1\u2013infected Ugandan children","volume":"29","author":"Musiime","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180306121514_CIT0025","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.7448\/IAS.15.6.18085","article-title":"Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up","volume":"15","author":"Violari","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180306121514_CIT0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/INF.0000000000000544","article-title":"Virologic failure among children taking lopinavir\/ritonavir-containing first-line antiretroviral therapy in South Africa","volume":"34","author":"Meyers","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180306121514_CIT0027","doi-asserted-by":"crossref","first-page":"e0133452","DOI":"10.1371\/journal.pone.0133452","article-title":"Factors associated with the development of drug resistance mutations in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy in South Africa","volume":"10","author":"Rossouw","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121514_CIT0028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/cid\/ciw213","article-title":"Antiretroviral drug resistance among children and youth in the United States with perinatal HIV","volume":"63","author":"Van Dyke","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/INF.0b013e31826fd3e7","article-title":"Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth","volume":"31","author":"Wong","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180306121514_CIT0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0000000000000568","article-title":"Single genome analysis for the detection of linked multiclass drug resistance mutations in HIV-1-infected children after failure of protease inhibitor-based first-line therapy","volume":"69","author":"Lange","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121514_CIT0031","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/cid\/cit696","article-title":"Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years","volume":"58","author":"Nachman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121514_CIT0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/INF.0b013e31824580e8","article-title":"Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1\u2013infected children and adolescents","volume":"31","author":"Briz","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180306121514_CIT0033","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1093\/jpids\/piu146","article-title":"Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type 1\u2013infected children 4 weeks to 2 years of age","volume":"4","author":"Nachman","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key\n\t\t\t\t20180306121514_CIT0034","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180306121514_CIT0035","doi-asserted-by":"crossref","first-page":"e0131541","DOI":"10.1371\/journal.pone.0131541","article-title":"Stability of HIV-1 nucleic acids in dried blood spot samples for HIV-1 drug resistance genotyping","volume":"10","author":"Aitken","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121514_CIT0036","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1128\/JCM.00544-14","article-title":"Field study of dried blood spot specimens for HIV-1 drug resistance genotyping","volume":"52","author":"Parry","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180306121514_CIT0037","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/cid\/cix194","article-title":"Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations","volume":"64","author":"Penazzato","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_9\/S838\/24264770\/jix407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T12:15:38Z","timestamp":1520338538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_9\/S838\/4555079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":37,"journal-issue":{"issue":"suppl_9","published-online":{"date-parts":[[2017,10,17]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix407","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,15]]},"published":{"date-parts":[[2017,10,17]]}}}